Media: Lack of buyers' interest in Novo Holdings-owned Xellia Pharmaceuticals

Equity firms haven’t shown any noteworthy interest in buying Danish Xellia Pharmaceuticals, which is owned by Novo Holdings.

Photo: Xellia Pharmaceuticals / PR

Novo Holdings’ hopes of selling antibiotics producer Xellia Pharmaceuticals have run aground, Danish business daily Børsen has learned.

It had been estimated that selling the company could land the owner around DKK 8bn (USD 1.2bn), which would be double the price that Novo Holdings paid for Xellia back in 2013.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs